Cart
sales@molnova.com
NPT200-11
CAS No. 2227057-23-8
NPT200-11( —— )
Catalog No. M28510 CAS No. 2227057-23-8
NPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 393 | Get Quote |
|
| 10MG | 590 | Get Quote |
|
| 25MG | 1060 | Get Quote |
|
| 50MG | 1591 | Get Quote |
|
| 100MG | 2387 | Get Quote |
|
| 200MG | 3580 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNPT200-11
-
NoteResearch use only, not for human use.
-
Brief DescriptionNPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation.
-
DescriptionNPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. NPT200-11 can be used in studies about the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA).(In Vivo):In the Line 61 transgenic mouse model overexpressing human wild type ASYN, NPT200-11 (5 mg/kg; i.p.) results in a time-dependent and progressive reduction in retinal ASYN pathology. NPT200-11 reduced alpha-synuclein pathology in cortex, reduced associated neuroinflammation (astrogliosis), normalized striatal levels of the dopamine transporter (DAT) and improved motor function.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2227057-23-8
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Adecatumumab
Adecatumumab (MT201) is a whole-person IgG1 monoclonal antibody to human EpCAM. Adecatumumab has potential anticancer activity and can be used to study breast cancer.
-
R-E-D-V
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion.
-
AI3-17671
AI3-17671 can be used in recombinant androgen receptor competitive binding assays as an analytical natural, synthetic and environmental chemical.
